New York City, New York Sep 21, 2022 (Issuewire.com) - BOC Sciences recently highlighted its oligonucleotide GMP manufacturing and custom synthesis abilities, buoying optimism that commercialization of oligo therapeutics may proceed to the next stage sooner.
Oligonucleotide-based drugs continue to flow into developmental pipelines, and relatively large numbers are now being tested in humans and progressing through late-stage clinical studies. In parallel to these advances is the rise of many CDMOs producing GMP-grade oligos at large scales reliably and cost-effectively. BOC Sciences, equipped with manufacturing facilities spanning over 40,000 square feet in China, is a standout in this field.
BOC Sciences guarantees the high-quality provision of DNA, RNA, modified and special oligonucleotides to global customers. Some featured products are UNA and TINA oligonucleotides, light-activated oligonucleotides, chimeric oligonucleotides, etc., most of which have earned mass popularity in the industry. Considering that the in-stock oligonucleotides may fail to satisfy a wider scope of applications, BOC Sciences has launched a one-stop oligonucleotide custom development platform that is qualified to execute oligonucleotide synthesis, modification, purification, and characterization, which can seamlessly match the specific requirements of every customer.
All the oligonucleotide manufacturers have to get over problems of poor stability, easy degradation, high polarity, low specificity, and poor affinity for target mRNAs. BOC Sciences, without exception, has also struggled for efficient modification and synthesis tech to enhance the oligonucleotide stability and reduce toxic/side effects. Thankfully, it has developed a high-throughput oligo synthesis platform which is also the world-leading ultra-large-scale nucleic acid synthesis platform (1μmol-18000mmol). A wide range of nucleic acid synthesizers is available there, covering laboratory scale (ÄKTA oligopilot Plus ), pilot scale (Oligopilot™ 400 ), and commercial production scale (Oligoprocess). All synthesizers apply flow-through solid-phase synthesis technology and can be custom-made.
To give customers an overview of its core competitiveness, the BOC Sciences sales manager sums it up as follows:
- Advanced and comprehensive synthesis platforms: various chemical modifications (phosphorus sulfur (PS), sugar, 2'-MOE, ) to complete the custom synthesis of hundreds of different oligonucleotides.
- Strict quality control: world-class mass spectrometry equipment to ensure the correct oligonucleotide molecular sequences; advanced purification technologies to supply high-purity materials; ISO 9001 and ISO 13485 certified
- Considerate customer services: prompt response and quotations; smooth shopping site applicable to all devices; fast and reliable logistics...
With the vision to be the most trustworthy CDMO partner, BOC Sciences is consistently expanding its landscape of oligonucleotide manufacturing abilities. To further explore its expertise, please visit https://cdmo.bocsci.com/.
About
BOC Sciences has a professional team specializing in chemical development technologies. It has collaborated with influential drug research institutions and companies by providing helpful solutions encompassing process R&D, analytical development, synthesis, scale-up, or final product production for APIs or chemical macromolecules.
Media Contact
Linna Green account@bocsci.com 6314854226 New York City, New York https://www.bocsci.com/
